Branded and generic pharmaceuticals, and pharmaceutical research and development
Founded
March 1984; 40 years ago (1984-03) in Libertyville, Illinois, United States
Founder
Allen Chao, Ph.D. and David Hsia, Ph.D.
Defunct
2015 (2015)
Fate
2015 Irish tax inversion and merger with Allergan, Inc.
Successor
Allergan, plc
Headquarters
Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States
Number of locations
40 manufacturing facilities 27 global R&D centers
Area served
≈100 countries
Key people
Brenton L. Saunders (CEO and president) Paul Bisaro (executive chairman)
Products
Branded and generic pharmaceuticals
Revenue
US$13.062 billion (2014)
Operating income
US$1.090 billion (2014)
Net income
US$−1.63 billion (2014)
Total assets
US$6.881 billion (2014)
Total equity
US$28.335 billion (2014)
Number of employees
21,600 (2015)
Parent
Teva Pharmaceuticals
Website
www.actavis.com
Actavis Generics[1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis PLC markets brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women's Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease.[2] The company's products include Botox,[3] Namenda, Restasis,[4] Linzess, Bystolic,[5] Juvederm,[6] Latisse,[7] Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex,[8] Optive,[9] Natrelle,[10] Viibryd, Liletta, Saphris,[11] Enablex, Actonel, Androderm, Gelnique and others.
Actavis PLC also operates the world's third-largest generics business. The company has been ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the US through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers more than 200 products.[12] Actavis PLC is also developing biosimilars products in oncology and other therapeutic categories, and currently has five biosimilar products in development.[13] Actavis PLC has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also included Anda Inc, the fourth-largest US generic pharmaceutical product distributor in the United States.[14]
On June 15, 2015, Actavis plc changed its name to Allergan plc, but the company's U.S. and Canadian generics business will continue to operate under the Actavis name.[15] In July 2015, Allergan PLC announced it would sell its Generics division of the company, including Anda Inc,[16] to Teva Pharmaceuticals for $40.5 billion,[17][18] a transaction proposed for completion by the first quarter of 2016.[19]
^"Analyst cuts Allergan generics sales estimates as Teva deal close nears". FiercePharma. 16 June 2016.
^"Form 10K". Actavis plc.
^"Botox cosmetics". Allergan.
^"Restasis" (PDF). Allergan.
^Barr, Diana (18 February 2014). "Forest Labs to be sold for $25 billion". St. Louis Business Journal.
^"Juvederm". Allergan.
^"Latisse" (PDF). Allergan.
^"Ozurdex". Allergan.
^"Optive". Allergan.
^"Natrelle". Allergan.
^"Form 10K". Actavis plc.
^"Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES Patent Suit". First Word Pharma.
^John Carroll (18 February 2015). "Can Actavis deliver a promised $6B boost from this pipeline". Fierce Biotech.
^"Actavis Confirms Favorable Ruling In Generic Pulmicort Respules Patent Suit". First Word Pharma.
^Haggerty, Neil (2015-06-15). "Actavis Changes Name to Allergan After Deal for Botox Maker". WSJ. Retrieved 2015-08-07.
^"Teva Completes Acquisition of Actavis Generics". www.businesswire.com. 2016-08-02. Retrieved 2019-03-06.
^"Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion" (Press release). Allergan. 27 July 2015. Retrieved 4 December 2015.
^Yoel, Minkoff (27 July 2015). "Teva to buy Allergan Generics for $40.5B". Seeking Alpha. Retrieved 4 December 2015.
^O'Donnell, Carl (3 December 2015). "Teva divesting $1 billion in assets to clear Allergan deal". Reuters. Retrieved 4 December 2015 – via Yahoo! Finance.
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical...
Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name. In 2016, Allergan sold its generic drugs business, Actavis, to...
issued an injunction, preventing Actavis from withdrawing the IR version until generic versions could launch. Actavis appealed and in May a panel of the...
by Watson Pharmaceuticals. See Actavis Acquisition and Watson Name Change, and Allergan, Inc. Acquisition and Actavis, plc Name Change DeNoon, D. (August...
the company was acquired by, and combined with, Actavis plc. On March 17, 2015 (2015-03-17), Actavis completed the acquisition of Allergan, creating a...
S2CID 32700350. "Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product". Actavis—a global, integrated...
2017, the company's Accord Healthcare announced acquisition of Actavis UK Ltd. and Actavis Ireland Ltd from Teva Pharmaceutical Industries, for an enterprise...
finding that from October 2008 onwards, drug suppliers Auden McKenzie and Actavis plc had charged "excessive and unfair prices" for 10mg and 20mg tablets...
international operations. In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million. Aurobindo Pharma plans...
2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis. This drug is contraindicated in case of having: Blockage of the gallbladder...
sale in the United States. On July 1, 2014, the company was acquired by Actavis (now Allergan). The company was founded by Hans Lowey in 1956 as a small...
healthcare and dermatology. On October 1, 2013, the company was acquired by Actavis (now Allergan). In 1968, Sir Allen McClay founded Galen, a sales and marketing...
4 November 2011. Retrieved 7 July 2011. "Buplex Pain Relief-Ibuprofen Actavis". Archived from the original on 18 February 2015. Retrieved 18 February...
executive officer of Actavis, a pharmaceutical company, after the company acquired Forest Laboratories. In November, Saunders negotiated Actavis' merger with...
sold in Eastern Europe under various trade names, including Spasmalgon (Actavis, Bulgaria), Revalgin (Shreya, India), Spasgan (Wockhardt, India), Bral...
the UK, Actavis marketed promethazine hydrochloride under the Sominex name. It was available at least as early as 1985 as an OTC hypnotic. Actavis also marketed...
Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Actavis UK Ltd. 24 March 2013. Archived from the original on 3 December 2013. Retrieved...
companies produced generic Adderall IR, while Teva Pharmaceutical Industries, Actavis, and Barr Pharmaceuticals manufactured generic Adderall XR. As of 2013[update]...
Mazda UK are; in the same building is Forest Laboratories UK (bought by Actavis in 2014), who make Veno's (cough mixture, the brand was bought from Beechams-GSK...
ISBN 978-0-9805790-9-3. "Buspirone 10mg Tablets". electronic Medicines Compendium. Actavis UK Ltd. 10 September 2012. Archived from the original on 13 November 2013...
however, in November 2014, Allergan announced that it would be acquired by Actavis in a $66 billion transaction. Valeant and Pershing Square were subsequently...
AstraZeneca. "Actavis Generic Prostate Cancer Drug Bicalutamide First to Market in UK, Germany, France". Press Release. AstraZeneca, Actavis. 10 July 2008...
in 2009 by Robert Wessman, who stepped down from his position as CEO of Actavis in order to found the company. Soon after its founding it had 200 products...
Global Information
US$1.090 billion (2014)
US$−1.63 billion (2014)